News Item

  • Press Release
  • February 11, 2021

New PrismRA® blood test enables providers to identify optimal approach to rheumatoid arthritis treatment FEBRUARY 11, 2021 – WALTHAM, MA...

News Item

  • Press Release
  • February 3, 2021

First-Of-Its-Kind Lab Test Helps Guide Targeted Treatment Decisions in Rheumatoid Arthritis FEBRUARY 3, 2021 – WALTHAM, MA – Scipher Medicine, a...

News Item

  • Article
  • January 15, 2021
  • https://www.healio.com/news/rheumatology/20210114/precision-medicine-arrives-in-ra-biomarker-test-predicts-tnf-inhibitor-response

By: Rob Volansky If there was any question about whether rheumatologists would utilize an effective biomarker that can predict response...

News Item

  • Press Release
  • December 7, 2020

Nine out of 10 responding rheumatologists stated the test would increase their confidence when making prescribing decisions WALTHAM, Mass. –...

News Item

  • Press Release
  • October 8, 2020

Dr. Regina Benjamin to Advise on Access to Precision Medicine Driving Better Health Outcomes for Patients with Autoimmune Diseases OCTOBER...

News Item

  • Press Release
  • September 17, 2020

PrismRA® first-of-its-kind molecular signature test validated in Ambry’s central laboratory. Partnership provides infrastructure for rapid scaling and patient accessibility.

News Item

  • Publication
  • September 14, 2020

Scipher Medicine is a spin-out of Northeastern University founded on the basis of, first, building a map of human biology...

News Item

  • Event
  • August 27, 2020

AMCP Science & Innovation Theater Webinar Speakers: James T. Kenney, MBA, RPh, President, JTKENNEY, LLC Alif Saleh, CEO, Scipher Medicine...

News Item

  • Press Release
  • July 28, 2020

PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy JULY 28, 2020- WALTHAM, MA- (Business Wire)- Scipher Medicine,...

News Item

  • Publication
  • July 14, 2020
  • https://www.liebertpub.com/doi/10.1089/nsm.2020.0007

Abstract Objectives: For rheumatoid arthritis (RA) patients failing to achieve treatment targets with conventional synthetic disease-modifying antirheumatic drugs, tumor necrosis factor...